Behcet's Disease Uveitis

被引:1
作者
Joubert, Morgane [1 ]
Desbois, Anne-Claire [1 ]
Domont, Fanny [1 ]
Ghembaza, Amine [1 ]
Le Joncour, Alexandre [1 ]
Mirouse, Adrien [1 ]
Maalouf, Georgina [1 ]
Leclercq, Mathilde [2 ]
Touhami, Sarah [3 ]
Cacoub, Patrice [1 ]
Bodaghi, Bahram [3 ]
Saadoun, David [1 ,4 ]
机构
[1] AP HP, Ctr Reference Malad Autoimmunes Syst Rares, Ctr Reference Maladies Autoinflammat & Amylose Inf, F-75013 Paris, France
[2] CHU Rouen, Internal Med Dept, F-76000 Rouen, France
[3] Sorbonne Univ, Pitie Salpetriere Univ Hosp, Dept Ophthalmol, F-75013 Paris, France
[4] Inst Natl Sante & Rech Med INSERM, Unite Med Rech UMRS 59, F-75013 Paris, France
关键词
Behcet's disease; uveitis; vasculitis; biotherapies; anti TNF-alpha agents; LONG-TERM EFFICACY; NECROSIS FACTOR-ALPHA; REFRACTORY UVEITIS; INTERFERON-ALPHA; INTRAVITREAL INFLIXIMAB; OCULAR MANIFESTATIONS; NONINFECTIOUS UVEITIS; CYCLOSPORINE-A; REMISSION INDUCTION; ADALIMUMAB THERAPY;
D O I
10.3390/jcm12113648
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Uveitis in Behcet's disease (BD) is frequent (40% of cases) and is a major cause of morbidity. The age of onset of uveitis is between 20 and 30 years. Ocular involvement includes anterior, posterior, or panuveitis. Uveitis may be the first sign of the disease in 20% of cases or it may appear 2 or 3 years after the first symptoms. Panuveitis is the most common presentation and is more commonly found in men. Bilateralization usually occurs on average 2 years after the first symptoms. The estimated risk of blindness at 5 years is 10-15%. BD uveitis has several ophthalmological features that distinguish it from other uveitis. The main goals in the management of patients are the rapid resolution of intraocular inflammation, the prevention of recurrent attacks, the achievement of complete remission, and the preservation of vision. Biologic therapies have changed the management of intraocular inflammation. The aim of this review is to provide an update to a previous article by our team on pathogenesis, diagnostic approaches, and the therapeutic strategy of BD uveitis.
引用
收藏
页数:20
相关论文
共 165 条
[1]   Comparison between optical coherence tomography angiography and fluorescein angiography findings in retinal vasculitis [J].
Abucham-Neto J.Z. ;
Torricelli A.A.M. ;
Lui A.C.F. ;
Guimarães S.N. ;
Nascimento H. ;
Regatieri C.V. .
International Journal of Retina and Vitreous, 4 (1)
[2]   Optical Coherence Tomography Angiography Findings in Active and Inactive Ocular Behcet Disease [J].
Accorinti, Massimo ;
Gilardi, Marta ;
De Geronimo, Daniele ;
Iannetti, Ludovico ;
Giannini, Daniela ;
Parravano, Mariacristina .
OCULAR IMMUNOLOGY AND INFLAMMATION, 2020, 28 (04) :589-600
[3]   Interferon alfa-2a in the treatment of Behcet disease - A randomized placebo-controlled and double-blind study [J].
Alpsoy, E ;
Durusoy, C ;
Yilmaz, E ;
Ozgurel, Y ;
Ermis, O ;
Yazar, S ;
Basaran, E .
ARCHIVES OF DERMATOLOGY, 2002, 138 (04) :467-471
[4]   Intravitreal Adalimumab for Refractory Uveitis-Related Macular Edema [J].
Androudi, Sofia ;
Tsironi, Evangelia ;
Kalogeropoulos, Christos ;
Theodoridou, Athina ;
Brazitikos, Periklis .
OPHTHALMOLOGY, 2010, 117 (08) :1612-1616
[5]  
[Anonymous], 2018, Drug Ther Bull, V56, P38, DOI 10.1136/dtb.2018.4.0604
[6]  
Arida A, 2022, CLIN EXP RHEUMATOL, V40, P1575, DOI 10.55563/clinexprheumatol/avhxp6
[7]   Anti-TNF Agents for Behcet's Disease: Analysis of Published Data on 369 Patients [J].
Arida, Aikaterini ;
Fragiadaki, Kalliopi ;
Giavri, Eirini ;
Sfikakis, Petros P. .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2011, 41 (01) :61-70
[8]   Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behcet's Disease: National Multicenter Study of 177 Cases [J].
Atienza-Mateo, Belen ;
Luis Martin-Varillas, Jose ;
Calvo-Rio, Vanesa ;
Demetrio-Pablo, Rosalia ;
Beltran, Emma ;
Sanchez-Burson, Juan ;
Mesquida, Marina ;
Adan, Alfredo ;
Victoria Hernandez, Maria ;
Hernandez-Garfella, Marisa ;
Valls-Pascual, Elia ;
Martinez-Costa, Lucia ;
Sellas-Fernandez, Agusti ;
Cordero-Coma, Miguel ;
Diaz-Llopis, Manuel ;
Gallego, Roberto ;
Garcia-Serrano, Jose L. ;
Ortego-Centeno, Norberto ;
Herreras, Jose M. ;
Fonollosa, Alejandro ;
Garcia-Aparicio, Angel M. ;
Maiz-Alonso, Olga ;
Blanco, Ana ;
Torre-Salaberri, Ignacio ;
Fernandez-Espartero, Cruz ;
Jovani, Vega ;
Peiteado, Diana ;
Pato, Esperanza ;
Cruz, Juan ;
Fernandez-Cid, Carlos ;
Aurrecoechea, Elena ;
Garcia-Arias, Miriam ;
Castaneda, Santos ;
Caracuel-Ruiz, Miguel A. ;
Montilla-Morales, Carlos A. ;
Atanes-Sandoval, Antonio ;
Francisco, Felix ;
Insua, Santos ;
Gonzalez-Suarez, Senen ;
Sanchez-Andrade, Amalia ;
Gamero, Fernando ;
Linares Ferrando, Luis F. ;
Romero-Bueno, F. ;
Javier Garcia-Gonzalez, A. ;
Almodovar Gonzalez, Raquel ;
Minguez Muro, Enrique ;
Carrasco-Cubero, Carmen ;
Olive, Alejandro ;
Prior, Agueda ;
Vazquez, Julio .
ARTHRITIS & RHEUMATOLOGY, 2019, 71 (12) :2081-2089
[9]   Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behcet's disease: multicentre retrospective study [J].
Atienza-Mateo, Belen ;
Calvo-Rio, Vanesa ;
Beltran, Emma ;
Martinez-Costa, Lucia ;
Valls-Pascual, Elia ;
Hernandez-Garfella, Marisa ;
Atanes, Antonio ;
Cordero-Coma, Miguel ;
Miquel Nolla, Joan ;
Carrasco-Cubero, Carmen ;
Loricera, Javier ;
Gonzalez-Vela, Maria C. ;
Vegas-Revenga, Nuria ;
Fernandez-Diaz, Carlos ;
Demetrio-Pablo, Rosalia ;
Dominguez-Casas, Lucia C. ;
Martin-Varillas, Jose Luis ;
Palmou-Fontana, Natalia ;
Hernandez, Jose L. ;
Gonzalez-Gay, Miguel A. ;
Blanco, Ricardo .
RHEUMATOLOGY, 2018, 57 (05) :856-864
[10]  
Atzeni F, 2015, IMMUNOTHERAPY-UK, V7, P353, DOI [10.2217/IMT.15.4, 10.2217/imt.15.4]